Anti-infective Acquisition Costs for a Stewardship Program: Getting to the Bottom Line | Zendy

Sarah K. Parker | Zendy; Amanda L. Hurst | Zendy; Cary Thurm | Zendy; Matthew Millard | Zendy; Timothy C Jenkins | Zendy; Jason Child | Zendy; Casey Dugan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-infective Acquisition Costs for a Stewardship Program: Getting to the Bottom Line

Author(s) -

Sarah K. Parker,

Amanda L. Hurst,

Cary Thurm,

Matthew Millard,

Timothy C Jenkins,

Jason Child,

Casey Dugan

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix631

Subject(s) - medicine , stewardship (theology) , line (geometry) , antimicrobial stewardship , microbiology and biotechnology , antibiotic resistance , biology , antibiotics , geometry , mathematics , politics , political science , law

Though antimicrobial stewardship programs (ASPs) are in place for patient safety, financial justification is often required. In 2016, the Infectious Diseases Society of America (IDSA) recommended that anti-infective costs be measured by patient-level administration data normalized for patient census. Few publications use this methodology. Here, we aim to compare 3 methods of drug cost analysis during 3 phases of an ASP as an example of this recommendation's implementation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research